Mini Oral session 2
Q&A and live discussion
Date
12 Dec 2020Session
Mini Oral session 2Presenters
All SpeakersAuthors
A. SpeakersAuthor affiliations
- /US
Resources
Resources from the same session
33MO - A phase I study of SHC014748M capsules in patients with relapsed or refractory indolent B-cell malignancies
Presenter: Wei Xu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
63MO - TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
Presenter: Christophe Le Tourneau
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
64MO - A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Joseph Sacco
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
65MO - A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
Presenter: Julia Katharina Schwarze
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 33MO and 63MO
Presenter: Camille Bigenwald
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: All Speakers
Session: Mini Oral session 2
Resources:
Webcast
Invited Discussant 64MO and 65MO
Presenter: Samra Turajlic
Session: Mini Oral session 2
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.